#Bristol Myers Squibb

Opdivo plus Yervoy led to higher response rates and longer survival than Opdivo alone.

Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.

Stop me if you’ve heard this one before.

The NAFLD/NASH medications’ page includes specific information about each of the experimental dru...

Half of people with worse liver function responded well to immunotherapy.

The median survival exceeded 15 months for patients previously treated with the only approved first-line therapy.

What new therapies are being developed by the major players in hepatitis C pharmaceuticals?

FDA has expanded the approved uses of the hepatitis C virus regimen of Bristol-Myers Squibb’s Daklinza and Gilead’s Sovaldi (sofosbuvir).

The European Commission has approved new indications for BMS’s Daklinza to treat hepatitis with Sovaldi, with or without ribavirin.

The Indian company has become the first drug maker in the country to receive approval to manufacture daclatasvir as a treatment for...

Highlights from presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.

Daklinza (daclatasvir) and Sovaldi (sofosbuvir) more effectively cures hepatitis C among those coinfected with HIV than does Sovaldi and...

The FDA as given priority review status to BMS’s applications for new indication approvals for the hep C drug virus Daklinza.

The FDA has approved BMS’s Daklinza (daclatasvir) to be used with Gilead Sciences’ Sovaldi (sofosbuvir) to treat genotype 3 of hepatitis C.

Bristol-Myers Squibb’s daclatasvir, asunaprevir and beclabuvir cured high rates of hepatitis C virus (HCV) among those with genotype 1...